J&J Partnership, page-354

....and yet another stem cell partnership (from an investment house). Its as if the investment community (outside of Australia) actually have a clue of the potential of regenrative medicine's effects on the landscape of medical treatments:

https://www.fiercebiotech.com/cro/ncardia-inks-60m-funding-deal-to-expand-discovery-and-commercial-production-services-for-stem

Roche "At Roche we are utilizing the enormous potential of human stem cells to test potential new drugs in vitro"
Bristol-Myers Squibb "cell-based therapies that use a person’s own cells are unlocking new potential in the fight against some of the most difficult-to-treat cancers...autologous chimeric antigen receptor (CAR) T cell therapy"
Pfizer "for more than a decade, Pfizer has been using animal or adult stem cells in its laboratories to help screen new compounds and identify safer and more effective medicines"
Eli Lilly - stem cells in diabetes; Astra Zenica - oncology etc, etc, etc

Partnerhsip between:

Biogen/Sangamo
J&J (Janssen)/Fate
Novartis/Sangamo
Bayer/Atara
Sanofi/Aventis
Novartis/Mesoblast (maybe!)
Fujifilm/Cynata
Sanofi/Kadmon
etc, etc.

The use of stem-cells, be they tissue specific, emryonic, and autologous, induced pluripotent or otherwise are taking off in development.

Johnson and Johnson's vaccine received a bit of furore over using fetal (retinal) embryonic cells in the research that led to its vaccines. Ironically the media overlooked Pfizer/Moderna's use of the fetal cell line HEK-293 in the confirmation phase to ensure the vaccines work.

Emryonic and other stem-cells are, quietly, increasingly being used in the labs of big Pharma in much of their research. There is little chance J&J leaves this very morally acceptable treatment of using a patients own stem-cells in a safe and very convenient way to address degenerative tendons. Its such an easy, uncontentioius and quick commercial possibility compared to most stem-cell treatments.